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Development of mobile composition of matter (MCM)-41 silica nanoparticles faces 
challenges, e.g. surface charge properties, antigen loading efficiency, protecting from enzymes 
and harsh GIT environment and effective release at target mucosal site. We report the 
production and characterization of polymer and amine modified MCM-41 type silica 
nanoparticles for oral antigen delivery and with ovalbumin (OVA) as model antigen. 
Nanoparticles were characterized by dynamic light  scattering (DLS), differential scanning 
calorimetry, X-ray diffraction, scanning electron microscopy (SEM), Brunauer-Emmett-Teller 
(BET), circular dichroism (CD), sodium dodecyl sulfate–polyacrylamide gel electrophoresis 
(SDS-PAGE), mucin binding, stability in simulated gastric fluid (SGF) and simulated intestinal 
fluid (SIF) and in vitro OVA release in SGF and SIF. Unmodified nanoparticles size 146nm 
increased to 175-321nm after modification while modified particles remained intact for more 
than 3 hrs in SGF and 96 hrs in SIF (DLS and SEM). Mucin binding proved PEG and chitosan 
modified nanoparticles as potential candidates for mucosal oral delivery. Both showed highest 
OVA encapsulation at 67% and 73%, and sustained OVA release in SIF (96 hrs) at 65% and 
64% respectively. BET results showed that nanopores were not blocked during surface 
modification. CD and SDS-PAGE showed that OVA conformational structure did not change 
after release from nanoparticles.  
 
Keywords: chitosan, nanocarrier, ovalbumin, mucoadhesive vaccine delivery, polyethylene 
glycol, silica surface modification.  




1. Introduction  
Since the discovery of MCM- mobile composition of matter (MCM)-41mesoporous silica 
nanoparticles (MSNs) in 1992, scientists have made tremendous efforts at exploring its 
potential application in biomedical research [1]. The delivery of specific protein into cells to 
influence cellular function requires a multifunctional cargo carrier which is able to 
encapsulate antigen and tailor it for targeting specific cells or tissues [2]. In this respect, silica 
nanoparticles have attracted considerable interest due to their biocompatibility, low toxicity, 
large surface area, pore volume, controlled release and stability in biological fluids. Another 
advantage of MSNs is the high internalization within various immune cells via endocytosis 
compared to other competing carriers, e.g. polymeric or synthetic organic materials [3]. 
However, several barriers have to be overcome to allow efficient antigen delivery because  
protein antigens are impermeable to cell membranes due to electrostatic repulsion and 
degradation or inactivation in body fluids [4]. Due to their structure and ability to protect 
encapsulated antigens from premature degradation in biological fluids, MSNs could be 
employed to increase efficiency of antigen delivery in vivo by avoiding antigenic protein 
denaturation [5] Protein encapsulation in MSNs is still challenging due to the small pore 
diameter (< 3nm) preventing protein molecules from entering the interior pores of the MSNs 
[6]. An alternative option is to design MSNs which would have large enough pores and  
internal surface area to allow protein molecules to be adsorbed and protected more effectively 
[7]. Research studies have shown that particles with size range of 50-200nm have achieved 
better uptake by endocytosis than particles with size greater 200nm [8].  
MSNs can especially achieve higher endocytosis for intracellular antigen delivery, 
when they are functionalized with positively charged moieties such as amine groups, 
polyethylene glycol (PEG) and polyethyleneimine (PEI) [9]. These functional groups have 
been used to modify MSNs surface properties to achieve adjustable stimuli responsive delivery 




systems based on environmental factors such as pH, enzymes, light and thermal (temperature) 
stability [10] as well as achieve higher protein encapsulation efficiency or higher binding 
capacity with nanoparticles [11]. 
To produce silica nanoparticles with suitable properties, sol-gel process has typically 
been used, specifically, MCM-41 type MSNs fabrication by soft templating method with two-
dimensional hexagonal structure and pore sizes > 2nm. In this method, tetraethyl orthosilicate 
(TEOS) is used as a silica source, the cationic surfactant cetyltrimethylammonium bromide 
(CTAB) used as a soft template and an alkaline compound as a catalyst [12]. Generally, MCM-
41 type MSNs have particle size less than 300nm, which has great potential for efficient 
immune cell internalization in antigen delivery research [13]. However, a major limitation of 
MCM-41 type MSNs is aggregation and various research studies have used different kinds of 
bases to catalyze the hydrolysis and condensation of TEOS to form colloidal complexes and 
modify their surface properties to prevent particle aggregation. The synthesis of amino 
functionalized dendrimer-like silica nanoparticles using sol-gel synthesis procedure, with 
TEOS as silica precursor, CTAB as a surfactant, ammonia as a catalyst, and 3-
aminopropyltriethoxysilane (APTES) as functional modification agent in an ethyl-ether-water 
system was reported [14] and produced MSNs with particle size range of 200-700nm and pore 
sizes > 4nm.  
To date, very few studies have focused on surface functionalization of MCM-41 
nanoparticles to achieve optimum mucoadhesive performance for effective mucosal vaccine 
delivery. Therefore this study seeks to enhance high antigen encapsulation and minimize 
agglomeration properties due to their high surface area and large pore volume, modify the 
MCM-41 particle surface to provide a rigid framework and suitable protection of 
encapsulated antigen from the harsh GIT environment (acidic pH and presence of proteases). 
In addition, surface modified nanoparticles are expected to provide sustained release of 




loaded antigen in the intestinal environment and reduce flocculation that can occur via non-
specific binding of active functional groups on MCM-41 nanoparticles’ surface. This study 
involves the synthesis of MSNs and investigation and comparison of the effect of surface 
modification using four different organic materials on nanoparticles properties. Specifically, 
the surfactant templating method was chosen to synthesize MSNs of approximate size 
ranging between 120 and 450nm. Hydrophobic MCM-41 nanoparticles were surface 
modified with four different materials: APTES, poly(methyl methacrylate) (PMMA), PEG, 
and chitosan to obtain partially hydrophobic, mucoadhesive and stable shells to promote 
sustained release of encapsulated model antigen. In addition, the effect of functionalization 
on the surface properties of the nanoparticles particularly their surface charge, hydrophilicity 
character, protein loading efficiency, protein release properties, stability in physiological 
fluid and formation of the protein corona that modulates their biological activity were 
investigated.   
 
2. Materials and Method 
Tetraethyl orthosilicate (TEOS, >99%, M.W. 208.33), cetyltrimethylammonium bromide 
[(CTAB), >99%,  M.W. 364.45), sodium hydroxide (NaOH) ≥ 97.0% pellets,  M.W. 40.00, 3-
aminopropyl-triethoxysilane (APTES, > 98% M.W. 221.37 ), polyethylene glycol (PEG) M.W. 
16000-24000, chitosan (75-85% deacetylated, M.W. 190,000-310,000), poly(methyl 
methacrylate-co-methacrylic acid) (PMMA, ratio 1: 0.016, M.W. 15000), OVA from chicken 
egg white (≥ 98%, M.W. 44287Da.), pepsin from porcine gastric mucosa,, mucin (0.5-1.5 % 
bound sialic acid) from porcine stomach, sodium chloride, acetic acid, sodium acetate, sodium 
dihydrogen phosphate, hydrochloric acid, maleic acid (≥ 99%, M.W. 116.07), were obtained 
from Sigma-Aldrich, (Gillingham, UK). Quick Start™ Bradford protein assay reagent was 
purchased from Bio Rad, (Watford, UK). All other reagents were of analytical grade. 




2.1 Synthesis of MCM-41 nanoparticles 
 MCM-41 type silica nanoparticles were synthesized as previously reported [15] with slight 
modifications. The basic synthesis of MSNs was conducted by mixing the silica source, 
(TEOS) with the templating surfactant (CTAB) in ultrapure double distilled water. In a round 
bottom flask, 833mg of CTAB was dissolved in 100ml double distilled water, 1.5ml of 2M 
NaOH standard solution was added and the resulting solution was heated at 80°C for 30 min 
whilst being stirred vigorously. After that, 0.4ml of TEOS was added dropwise into the CTAB 
solution and stirred at 80°C for a further 2 hrs. After formation of a white cloudy suspension, 
the temperature was slowly reduced with continuous stirring (4 hrs) until the temperature was 
stabilized at room temperature. The white precipitate (MCM-41 nanoparticles) was collected 
by centrifugation at 20,000rpm and washed with methanol 3 times at the same rpm to remove 
excess surfactant. The collected sample (pellet) was designated as MCM-41 nanoparticles.  
 For amine surface modification, 2g of the MCM-41 was dispersed in 90ml deionized 
water and 10ml APTES was added dropwise into the resulting dispersion and stirred for 24 hrs 
under temperature-controlled water bath at 20°C. The formulation was then centrifuged and 
washed with methanol 3 times to remove surfactants and unbound APTES. For the PEG 
modification, 100mg of PEG was dissolved in 100ml of a 50:50 dioxane: water solution at 
room temperature and approximately 2g of MCM-41 MSNs dispersed in the PEG solution and 
stirred for 24 hrs. PEG has two reactive ends and one reactive end can be attached to the particle 
surface and limits the coupling process only to one end. For PMMA modification, MCM-41 
MSN (2g) was dispersed in 90ml water and 10ml PMMA added dropwise and stirred at room 
temperature for 24 hrs. PMMA modified MCM-41 nanoparticles were collected by 
centrifugation at 20000rpm. After centrifugation, white solid particles (pellet) were deposited 
at the bottom of centrifuge tube which was recovered by discarding the supernatant. The 
collected pellet was washed three times with water by centrifugation as described before. For 




chitosan modification 100mg chitosan was dissolved in 90ml acetic acid solution (1.0%) and 
2g MCM-41 white particles dispersed in the chitosan solution and vigorously stirred for 24 hrs 
and then washed with water 3 times via centrifugation.    
 
2.2 Protein encapsulation studies  
OVA stock solution (0.5mg/mL) was prepared in phosphate buffer (pH 7.4). Plain MCM-41 
and surface modified equivalents (2mg/mL) were sonicated (5 min) and dispersed in the same 
buffer. In a typical procedure, 0.5mg/ mL of the OVA stock solution was mixed with 2mg/ml 
of MCM-41, MCM-41 APTES, MCM-41-PMMA, MCM-41-PEG and MCM-41-chitosan 
suspensions and incubated in a water bath shaker (400rpm, 20 °C). After overnight incubation, 
protein-loaded particles (were collected by centrifugation (13 000 rpm, 30 min) and separated 
from the non-encapsulated (free) protein, which remained in the supernatant. The encapsulation 
efficiency (EE%) was determined by measuring the difference in concentration of the protein 
in the supernatant before and after loading. The concentration of protein was determined by 
Bradford assay using a standard calibration curve of OVA. The intrinsic fluorescence intensity 
and absorbance were measured using 96-well plate in a plate reader (Thermo Fisher multiskan, 
photometer). The standard curves were based on the absorbance of OVA within the 
concentration range of 0.1mg/ml to 3mg/ml. The calibration curves were based on the 
absorbance at 620 and 540, respectively, as a function of concentration. The EE (%) and 
loading capacity (LC) (%) were calculated as shown in equations 1 & 2.  
 
𝐄𝐄 (%) =
𝐭𝐨𝐭𝐚𝐥 𝐚𝐦𝐨𝐮𝐧𝐭 𝐨𝐟 𝐎𝐕𝐀−𝐟𝐫𝐞𝐞 𝐎𝐕𝐀 𝐢𝐧 𝐬𝐮𝐩𝐞𝐫𝐧𝐚𝐭𝐞𝐧𝐭 
𝐭𝐨𝐭𝐚𝐥 𝐚𝐦𝐨𝐮𝐧𝐭 𝐨𝐟 𝐎𝐕𝐀
× 𝟏𝟎𝟎    (1) 
 
𝐋𝐂 (%) =
𝐭𝐨𝐭𝐚𝐥 𝐚𝐦𝐨𝐮𝐧𝐭 𝐨𝐟 𝐎𝐕𝐀−𝐟𝐫𝐞𝐞 𝐎𝐕𝐀 𝐢𝐧 𝐬𝐮𝐩𝐞𝐫𝐧𝐚𝐭𝐞𝐧𝐭
𝐃𝐫𝐢𝐞𝐝 𝐧𝐚𝐧𝐨𝐩𝐚𝐫𝐭𝐢𝐜𝐥𝐞𝐬 𝐰𝐞𝐢𝐠𝐡𝐭 
× 𝟏𝟎𝟎    (2) 
 




2.3 In-vitro protein release study  
To determine the amount of protein released from OVA loaded nanoparticles, the Bradford 
reagent (protein-specific dye, Coomassie brilliant blue) was used and analyzed with 96-well 
polystyrene plate as above and performed in triplicate. Freeze dried OVA loaded nanoparticle 
(5mg|) were dispersed in 0.01% sodium azide containing 2ml of SGF (pH 1.2) and SIF pH 
6.8) and were incubated at 37°C in bath shaker with gentle stirring. At pre-determined time 
intervals over 24 hrs, 0.1ml aliquots of dissolution media were collected and replaced with 
same amount of fresh simulated fluid. The samples were analyzed with plate reader at an 
absorbance of 595nm and Bradford reagent standard were used according to manufacturer’s 
instruction kit.  
 
2.3 Characterization 
2.3.1 Particle size and zeta potential evaluation using dynamic light scattering (DLS) 
DLS was used to measure particle size, polydispersity index (PDI) and zeta potential with the 
help of a Zetasizer Nano-ZS90 (Malvern Instruments, UK) using disposable cuvette for size 
and PDI analysis. Zeta potential was measured using the Malvern Zetasizer with a reusable 
folded capillary zeta cell, (Malvern Model: DTS1070) by determining the electrophoretic 
mobility. The sample was measured in deionized water and adjusted to a conductivity of 50 
S/cm with sodium chloride solution (0.9% w/v). The pH was 7.4 and the applied field strength 
was 20V/cm. The sample was properly diluted (1ml sample and 1ml deionized water) to 
achieve concentrations between 2 – 3 % w/w and scanned with constant refractive index 
viscosity and dielectric constant for all formulations at controlled temperature of 20°C. For 
each sample, 15 runs of 10 s were performed, with three repetitions for all the blank 
nanoparticles and protein loaded nanoparticles. The intensity of size distribution, the Z-average 




diameter (Z-ave) and the PDI were obtained from the autocorrelation function using the 
“general purpose mode.  
2.3.2 Morphology by scanning electron microscopy and scanning transmission electron 
microscopy  
The morphology of MCM-41 nanoparticles was examined by scanning electron microscopy 
(SEM) (Hitachi SU8030) at operating voltage of 1kV. In this study 1kV was found harmless 
for MCM-41 nanoparticles observation. One drop of freshly prepared particles suspensions 
was deposited on SEM sample stub and left until air dried and the dried sample was chromium 
coated for 3 min. For scanning transmission electron microscopy (STEM) analysis, the sample 
was diluted (1:2) and stained with 2% (w/v) phosphotungstic acid for 30 s and placed on copper 
grids with films for observation. The dried specimens were examined at high resolution for 
morphological characteristics of the nanoparticles. Excess liquid was removed by using filter 
paper before observation on the STEM machine.  
  
2.3.3 Attenuated total reflectance Fourier transform infrared (ATR-FTIR) spectroscopy 
Infrared absorption spectra were obtained for both pure starting materials and the formulated 
nanoparticles at room temperature. Attenuated total reflectance (ATR)-FTIR (Perkin Elmer, 
Spectrum Two) spectra were performed in transmittance mode (%T) mode, with 32cm−1 
resolution and scan speed of 0.2 over a wavelength range of 450–4000cm−1. The samples were 
placed on ZnSe ATR crystal and maximum pressure was applied using a pressure clamp 
accessory to allow intimate contact between the samples and the ATR crystal.   Different peaks 
in the IR spectrum were interpreted for different functional groups in the formulations.    
 
2.3.4 X-ray diffraction (XRD) 




X-ray diffraction was performed to investigate crystalline or amorphous nature of the 
formulated nanoparticles. The diffractograms were recorded with a Brucker AXS D8 Advance 
instrument using Cu-ka line as a source of radiation and operated at a voltage of 40keV and 
current of 35mA. Freeze dried formulated samples were measured in the range between 3º and 
50º 2θ for 2 hrs and step size of 0.02º and scan speed of 0.5s/step. 
 
2.3.5 Differential scanning calorimetry (DSC) 
DSC analysis (Mettler Toledo 823e, Greifensee, Switzerland)) was performed to characterize 
the physical state of the starting materials, lyophilized plain MCM-41 nanoparticles, surface 
modified MCM-41 nanoparticles and protein loaded nanoparticles. About 3mg of accurately 
weighed sample was placed into aluminium pans with lids and analyzed at a scanning 
temperature range from 0°C to 300°C and heating rate of 10°C/min under dry nitrogen 
atmosphere. The initial temperature of 0°C was maintained with the help of liquid nitrogen.   
 
2.3.6 Nanoparticles stability studies in SGF and SIF 
MCM-41 surface modified nanoparticles were analyzed for colloidal stability  in SGF and SIF 
and experiment performed by using previously reported method [16] with slight modification. 
The composition of SGF and SIF are provided in tables S1 and S2 (Supplementary data). 
Freeze dried MCM-41 nanoparticles was weighed (1mg/ml) into respective simulated fluid 
contained in a round shaped bottle and placed in shaking water bath (200rpm) at 37°C for 12 
and 96 hrs in the SGF and SIF respectively. At time intervals of 30 mins, both fluids were 
sampled, and particles analyzed for size using Zetasizer and by SEM to investigate the effect 
of pH and ions on size and shape of protein loaded nanoparticles over time. Measuring the size 
distribution of the surface modified nanoparticles in different simulated biological fluids at 
different time points helped to monitor any nanoparticle aggregation as an indicator of colloidal 




stability. Further, the withdrawn protein loaded MCM-41 nanoparticles suspension was passed 
through Millipore filter and the protein lost from the nanoparticles analyzed using Bradford 
assay as described above.     
2.3.7 In vitro mucin binding of (MCM)-41 surface modified nanoparticles.   
The mucoadhesive properties of MCM-41 nanoparticles were investigated as previously 
described [16], but with minor modification. Briefly, 0.5ml of mucin solution (0.5mg/ml) was 
mixed with 0.5ml of each surface modified MCM-41 nanoparticle suspension and incubated at 
37°C in a shaking water bath for 2 hrs. After centrifugation at 16000rpm for 40 min, the 
supernatant was collected, and the amount of free mucin was measured using Bradford protein 
assay. The supernatant was incubated with Bradford reagent for 5 min in a 96 well plate, after 
which the absorbance (620nm) was measured with a plate reader (Multiskan FC Microplate 
Photometer, Thermo Fisher Scientific). Mucin concentration was calculated from a standard 
curve of mucin in concentration range from 0.1 to 1.0mg/ml. The amount of mucin binding 
with nanoparticles was determined using equation (1) mentioned above.     
 
2.3.8 Circular dichroism analysis  
Circular dichroism (CD) spectra were obtained using a Chirascan spectrophotometer (Applied 
Photophysics Limited) to examine the secondary structure of OVA during the release period. 
Spectra were collected at 20°C using a quartz cell (path length 0.05cm) and the wavelength 
range of 180-260nm and a resolution of 0.2nm with 2.25 second response time. Each spectrum 
represents an average of four consecutive scans. Noise reduction, blank solution subtraction 
and data analysis were performed using standard analysis and temperature/wavelength analysis 
program (Origin pro 8, USA)). OVA was extracted from samples after 96 hrs in vitro release 
study by centrifuging at 5000rpm before CD analysis and compared with native OVA.     





2.3.9 Sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) analysis 
 One dimensional SDS-PAGE analysis was performed on OVA released from the MCM-41 
surface modified nanoparticles to determine primary structure after 96 hrs in SIF (pH 6.8). The 
gel (4-12%) was prepared by following a previously reported method [18]. Briefly, a separating 
gel prepared with 3.4ml deionized water, 2ml of 1.5M tris-HCl (pH 8.8), 2.4ml of 30% poly 
acrylamide, 100µl of 10% SDS, 100µl ammonium persulfate and 10µl of tetramethyl 
ethylenediamine was poured into the gel cassette (Bio-Rad). The whole assembly was left to 
stand for 15-20min to allow the gel to solidify and stacking gel was then poured on top of the 
separating gel and a 10-lane comb was added. Aliquots (20μl) of the OVA containing 
suspensions were mixed with similar volume of SDS loading buffer in a 1 ml centrifuge tube. 
The resulting mixture was then heated to 95 °C for 10 min in a heating block (DIGI-BLOCKTM) 
to denature the disulfide bonds of the proteins and cooled to room temperature and centrifuged 
to remove any suspended solids. Tris-HCl, pH 6.8, 1mM ethylenediamine tetraacetic acid 
(EDTA), 2-mercaptoethanol and bromophenol blue mixture, served as tracking agent. 2-
mercaptoethanol was the reducing agent and was responsible for breaking the disulfide bridges 
and denaturing the protein molecules. Aliquots (20μl) of the supernatant was then transferred 
on top of the gel in a Bio-Rad mini gel tank and both upper lower chambers were filled with 
SDS- running buffer. The gel run was performed at a constant voltage of 200V for 1 hour. The 
gel was stained with Coomassie blue staining solution and washed with 5% (v/v) acetic acid 
solution overnight and images captured by a BioDoc-It® Imaging System, (UVP, LLC, Upland, 
USA). 
  




2.3.10 Brunauer-Emmett-Teller (BET) analysis 
Freeze dried MCM-41 surface modified nanoparticles were investigated for pore volume, 
surface area and pore diameter by using BET (Micromeritics, Gemini VI) analysis. About 
60mg of sample was placed in the glass cell and degassed at 45ºC for more than 36 hrs with 
high vacuum pressure to remove water and contaminants before surface area was measured. 
The surface area was calculated by BET theory using isotherm adsorption data at P/P0 from 
0.0 to 0.3. Liquid nitrogen was used to cool the sample and maintained at a constant 
temperature of -196ºC. 
 
2.3.11 Statistical analysis 
All the quantitative data were analyzed by one-way ANOVA by using GraphPad Prism 
software (version 5.02). The level of significance was set at p < 0.05. 
 
3. Results and discussion  
3.1 Surface modification, DLS and protein loading analysis 
The surface of MCM-41 nanoparticles was modified by APTES, PMMA, PEG and chitosan to 
determine the interaction with other surfaces and to generate different electrochemical 
environments (negatively and positively charged) and their subsequent effect on particle size, 
PDI and zeta potential values. DLS measurements (Table 1) revealed that unmodified MCM-
41 nanoparticles were unimodal in distribution and possessed average hydrodynamic diameter 
in solution between 146 to 321nm but the size increased after surface modification.     
After functionalization by amino group (APTES) the surface charge changed from 
negative to positive with a zeta potential value from -37 to +33mV, while particle size changed 
from 146 to 175nm. This indicates that, protonated NH3
+ groups have dominance on the surface 
of MCM-41 which remains in the protonated state in the neutral deionized water media. After 




adding protein to the nanoparticles’ suspension, the surface charge properties changed from 
positive back to negative and zeta potential value from +33 to -45mV and particles size also 
increased from 175nm to 203nm. This is because OVA has a net negative charge and 
nanoparticle synthesis was conducted under neutral conditions. OVA EE also increased from 
32% for plain MCM-41 to 69% for surface modified MCM-41 APTES and could be due to 
positive and negative charge interaction between the OVA and APTES respectively. The size 
distribution of nanoparticles indicates homogenous distribution according to PDI values in 
Table 1. The rapid decline of charge properties after APTES modification of MCM-41 
nanoparticles is due to adsorbing more protein compared with unmodified MCM-41 
nanoparticles.       
 
MCM-41 PMMA modified nanoparticles showed, higher size at 211 ± 4nm and PDI of 0.47 ± 
0.10 and decreased zeta potential value of 17 ± 2mV after protein loading. In this case neutral 
charge properties of PMMA co-polymer affected the MCM-41 surface charge (negative to 
neutral) and colloidal stability (zeta potential) rapidly declined due to the polymer instability 
in aqueous media. In addition, PDI value indicated that the particle size distribution was 
multimodal and not homogenous. This suggests that, the electrostatic interaction between co-
polymer PMMA and MCM-41 nanoparticles reduced due to the neutral surface charge. The 
above result could be attributed to the fact that the organic polymer molecule blocked the pore 
channels of the MCM-41 particles. Interestingly, after OVA encapsulation, the surface charge 
of particles changed from neutral to negative due to OVA having its own negative charge 
properties which was dominant in the MCM-41-PMMA formulation but with a very low 
protein EE at 23%.  
Before functionalization, surface charge of the MCM-41 nanoparticles was negative 
and remained negative after PEG modification with particle size of 236 ± 5nm, PDI of 0.32 ± 




0.16 and zeta potential value -33 ± 6mV before protein loading. The phenomenon might be 
attributed to different chain lengths arising from the significant increase (p < 0.05) in particle 
size after modification, while the PDI value indicated homogenous particle size distribution. 
Further, after PEG modification, MCM-41 showed an increase in OVA EE from 39% to 67% 
due to changing surface charge after PEG modification (negative to positive) which had a 
strong electrostatic interaction with the highly negative encapsulated protein.  
After chitosan modification, particles size MCM-41 increased to 321 ± 11nm and zeta 
potential value changed from -37 ± 3 to 33 ± 4mV, which indicates that chitosan dominates in 
the modified MCM-41 nanoparticles. MCM-41 particles in water are negatively charged at the 
studied neutral media, because the hydroxyl groups on their surfaces are deprotonated. Both 
components (silica and chitosan) within this water pH range displayed intermediate charges 
and gradually become more positive as chitosan concentration increased due to the protonation 
of its amine group. In this study, 0.1% chitosan solution was employed for MCM-41 surface 
modification due to aggregation and formation of large particles at higher chitosan 
concentrations. After OVA loading, chitosan modified MCM-41 nanoparticles changed the 
surface properties from neutral to negative charge and zeta potential value and protein EE 
(74%) also increased and this might be because native OVA is negatively charged. During in 
situ modification of MCM-41 nanoparticles, hydrogen bonds between acetyl groups of the 
chitosan molecules and hydroxyl groups on the MCM-41 surface have been suggested to 
provide additional driving force for protein adsorption [19]. 
   
3.2 Morphology of MCM-41 modified nanoparticles 
SEM image of unmodified MCM-41 blank (Figure 1) nanoparticles and surface modified 
nanoparticles (Supplementary data, Figure S1A) demonstrate that both showed uniform and 
spherical shapes. It was also observed that there was no agglomeration of particles after surface 




modification. The size of polymer modified MCM-41 nanoparticles was slightly larger than 
unmodified MCM-41 nanoparticles. In addition, though the particle size from DLS 
measurement and SEM showed differences, they did not vary considerably as shown by the 
size distribution histogram (Figure 1B). After OVA encapsulation, nanoparticles showed 
agglomeration with the unmodified MCM-41 nanoparticles generally showing irregular shapes 
(figure 1, Image E), which suggests that protein adsorption or encapsulation by nanoparticles 
could cause aggregation. In comparing between blank and protein loaded nanoparticles using 
STEM, the images shown in figure 1, image C and image G, depicts homogenous blank 
nanoparticles which become non-spherical agglomerates after protein encapsulation. In figure 
S1B (Supplementary data), STEM image of blank nanoparticles showed smooth distinct shapes 
with clear distances between them, while protein encapsulated nanoparticles (Supplementary 
data, figure S1B), depict narrow particle size distribution.    
 
3.3 X-Ray Diffraction (XRD) analysis 
Investigation of plain MCM-41 nanoparticles, PMMA and chitosan surface modified MCM-
41 blank and protein encapsulated nanoparticles showed no sharp peaks suggesting they were 
amorphous in nature. Both PEG and APTES modified MCM-41 nanoparticles and their blank 
and OVA encapsulated nanoparticles in figure 2a and figure 2b showed reduction in sharp 
peaks after formulation of MCM-41 nanoparticles and surface modification compared to the 
pure starting materials (Figure S2, Supplementary data).  
 In addition, XRD pattern in figure 2b showed slight shifting of peaks from 26° to 23° 
2θ for the PEG modified MCM-41 nanoparticles. PMMA and chitosan modified MCM-41 
nanoparticles showed amorphous nature in both blank and OVA encapsulated particles, while 
the crystalline peaks was observed in PEG modified MCM-41 nanoparticles was in both blank 
and protein encapsulated formulations. In comparing the diffractograms of pure PEG 




(supplementary data) with both blank and OVA encapsulated PEG modified MCM-41 
nanoparticles, reduced peak intensities were observed in nanoparticle formulations. This can 
be attributed to pure OVA and unmodified MCM-41 nanoparticles both of which were 
amorphous in nature. The XRD results were complemented by DSC analysis data as shown in 
Figures S3, S4 and S5 (Supplementary data).  
3.4 ATR-FTIR 
The ATR-FTIR spectra of MCM-41 surface modified nanoparticles are shown in figures 3a 
and 3b, and that for pure materials (OVA, PEG, CTAB, chitosan) are shown in Figure S6 
(Supplementary data). The blank and OVA encapsulated nanoparticles showed absorption 
peaks arising from asymmetric vibration of Si-O-Si (1025cm-1, 1050cm-1) and asymmetric 
vibration of Si-OH (955cm-1, 910cm-1) associated with the formation of condensed silica 
structure  [20] [21]. The two bands with weak intensities at 2855 and 2922cm-1 can be attributed 
to the stretching vibrations of alkyl chains on the surface from the CTAB coating the MCM-
41 nanoparticles as was reported in (Mansfield et al., 2018) [22] A broad and intense peak at 
3315cm-1 is attributed to the stretching vibrations of hydrogen bonds and Si-OH groups 
covering the surface of the colloidal silica, H-bonding of H2O and H-bonded OH group. The 
OVA encapsulated MCM-41 showed various small peaks between 1600 and 1900cm-1 with the 
major one peak at 1656cm-1 being attributed to amide I (a represents a shift to higher 
wavelength from that of the pure OVA - 1638cm-1) and a smaller one at 1592cm-1 due to amide 
II of OVA. This confirms that the OVA has been encapsulated within the nanoparticles as 
intended. 
 Furthermore, peaks appearing at 1470cm-1 and 1710cm-1, were attributed to the 
stretching vibration of a primary carbonyl absorption peak and bending vibration peak of C-H 
of   OVA loaded MCM-41 nanoparticles. Figure 3a and 3b also exhibited a number of 
characteristic spectral bands, such as; the peaks at  578cm-1, 690cm-1 and 789cm-1 due to the 




asymmetric stretching vibration, symmetric stretching vibration and bending vibration of  Si-
O-Si , while the antisymmetric stretching vibration band around  980cm-1 is due to stretching 
vibration of Si-OH .  
APTES modified MCM-41 nanoparticles exhibited CH2 bending peaks at 1563cm
-1 
while the peaks at 2950 and 3300cm-1 corresponding to CH and NH stretching respectively. 
NH2 group derived from the APTES and NH stretching indicate the presence of amino groups 
in the MCM-41 nanoparticles. The PEG modified MCM-41 nanoparticles showed the 
incorporation of an ester linkage which is proved by the absorption peak at 1472cm-1. MCM-
41 PMMA modified nanoparticles sample showed peaks at 172 and 1467cm-1 assigned to the 
carbonyl (C=O) stretching and the CH2 bending modes, and an absorption peak of Si-O-Si 
vibration at 1100cm-1 indicating (C-O-C) of PMMA overlapping with MCM-41 nanoparticles. 
The characteristic bands of benzene ring band around 1500cm-1 appeared weak in the spectra 
of MCM-41 PMMA nanoparticles. Chitosan modified MCM-41 nanoparticles showed band 
shifts from pure materials at 1810cm-1 representing NH2 group deformation vibration. Intensive 
absorbance at 1110cm-1 represents the Si-O stretching vibrations.  
 
3.5 In vitro protein release study 
The OVA from modified and unmodified MCM-41 nanoparticles was performed in SGF 
without pepsin (pH = 1.2) and SIF (pH = 6.8) at 37ºC and the results are presented in figures 
4a and 4b. Pepsin was not used in OVA encapsulated nanoparticles SGF analysis to avoid 
technical error caused by interference by pepsin in accurately measuring OVA molecule by 
Bradford protein assay. However, the stability analysis for the blank nanoparticles was 
performed in SGF containing pepsin (Figure S7, Supplementary data). The retention of protein 
activity after passing through the acidic environment of the stomach is a vital functional 
characteristic for an oral protein delivery carrier. However, to assure absolute stability of OVA 




in actual SGF containing pepsin, another protein analysis technique such as LC-MS, which 
will allow the distinguishing between pepsin in SGF and OVA from the nanoparticles, will be 
useful in the future.  
 Non-encapsulated and encapsulated OVA was found in SGF within 30 mins, with the 
release from PEG and chitosan modified MCM-41 nanoparticles being significantly delayed 
compared with unmodified and APTES and PMMA modified MCM-41 nanoparticles. In SGF 
(pH 1.2) 24% of OVA was released from plain MCM-41 within 30 mins and 40% protein 
within 2 hrs, whilst 25% and 20% of protein was released from MCM-41 PEG and MCM-41 
chitosan respectively within 2 hrs. This suggests that most of the encapsulated protein in MCM-
41-PEG and MCM-41-chitosan was protected from the gastric environment over a 2 hr period. 
 PEG modification of MCM-41 resulted in a higher protein release than chitosan due to 
PEGylating in the dispersion medium which favors protein diffusion [23] suggesting that OVA 
released from porous nanoparticles depend on the amount of OVA encapsulated into the 
nanoparticles and free pore volume. Various research papers [24, 25] showed that chitosan is 
more stable in GIT environment than other natural polymers. The retention time of particles in 
the stomach is between 1 and 2 hrs. Therefore, since the amount of OVA released at pH 1.2 
from PEG modified particles was 16-25% and 14-20% from chitosan modified it is important 
to optimize the system further in order to provide a minimum contact between gastric 
environment and protein and thus avoiding any possible protein denaturation. When 
nanoparticle powder was dispersed in SIF, OVA released from nanoparticles occurred at a 
slower rate compared with SGF. An initial burst release of protein from modified and 
unmodified MCM-41 nanoparticles within 1 hr, was followed by sustained release pattern with 
OVA released very slowly from the nanoparticles. The initial burst release of OVA molecules 
from MCM-41 nanoparticles could probably be due to the OVA molecules adsorbed on the 
surface. The reason for the gradual and sustained release of OVA molecules from modified 




MCM-41 nanoparticles may be explained as follows: silica nanoparticles after OVA 
incorporation increased in size which significantly reduced the release rate of OVA, which also 
applies to low molecular weight compounds as reported by other authors [26]. The MCM-41 
APTES, PEG and chitosan modified nanoparticles showed more sustained release pattern 
compared to unmodified and PMMA modified [27]. These differences may be attributed to a 
combination of factors, dependent on the silica architecture, including nanoparticles size, pore 
diameter and charged properties [28]. Meanwhile, the diffusion hindrance from long polymeric 
chain would prevent the incorporation of OVA molecules into the MCM-41 nanoparticles. 
APTES, PEG and chitosan modified MCM-41 nanoparticles showed micro pores resembling 
honeycomb structures which allowed the entry of OVA molecules into the nanoparticles, 
thereby improving interactions between OVA molecules and the nanocarriers leading to a 
slower release profile of OVA in SIF.                    
 
3.6 Stability analysis of MCM-41-nanoparticles in simulated fluid based on particle size, 
PDI and zeta potential:  
During formulation development of OVA encapsulated nanoparticles, it is very important that 
chemical and conformational structure of OVA is preserved in order to maintain the biological 
and pharmacological activity of the entrapped protein. Therefore, stability of the MCM-41 
surface modified nanoparticles in two different simulated fluid SGF and SIF was investigated 
at various time intervals by measuring nanoparticles size, PDI, zeta potential (DLS) and 
morphology (SEM). The stability of protein loaded MCM-41 nanoparticles evaluated are 
shown in Figure 5a for SGF and in figure 5b for SIF. Unmodified MCM-41 nanoparticles 
showed a slight decrease of particle size in SGF after 3 hrs but the nanoparticles were stable in 
SIF over 4 days as confirmed by SEM images (image not shown).  




 In SGF, the size of unmodified MCM-41 decreased (p > 0.05) from 146nm to 
137nm within 3 hrs and showed another steep decrease after 8 hrs and could not be observed 
by SEM analysis (SEM image not shown). However, the stability of silica nanoparticles in 
simulated fluids (SGF or SIF) is strongly dependent on pH. At pH values above 7, there is 
increased deprotonation of silanol groups and hydrolysis of Si-O-Si bonds which is catalyzed 
by nucleophilic attack of OH ions. Consequently, silica nanoparticles are more stable in SGF 
pH [29]. However, Valeti and co-workers reported that silica nanoparticles also comprise 
titratable SiOH groups which can protonate or deprotonate at neutral pH, and further that the 
particles respond to alkaline pH (>7) resulting in greater negative charges [30].  
 For APTES modified MCM-41 nanoparticles, the size was decreased (p > 0.05) 
from 175nm to 109nm after 8 hrs, while PDI and zeta potential values also decreased after 4 
hrs [25] demonstrating that amino group plays an important role in the erosion of silica 
nanoparticles. Figure 5a showed that PMMA, PEG and chitosan modified nanoparticles 
exhibited better stability than APTES and unmodified MCM-41 nanoparticles. After 12 hrs in 
SGF, polymer modified MCM-41 nanoparticles was observed by SEM (image not shown) and 
the nanoparticles shape did not indicate any aggregation or erosion. For MCM-41 PMMA 
nanoparticles, the size was 197nm after 12 hrs and slowly reduced in size after 10 hrs where 
the size was observed at 118nm. Furthermore, PDI and zeta potential values also decreased 
(data not shown). The MCM-41 PEG modified nanoparticles showed nanoparticles stability 
over 12 hrs but some aggregation was observed in SEM images after 8 hrs. After 2 hrs, 
nanoparticles size was measured at 214nm and after 10 hrs nanoparticles size reduced to 
180nm. The MCM-41 chitosan modified MCM-41 nanoparticles showed size of 316nm after 
2 hrs and 278 nm over 12 hrs.  
According to particles size analysis by DLS and SEM measurements the most stable 
formulations were MCM-41 PEG and chitosan modified nanoparticles. As was the case for 




SIF, PEG and chitosan modified nanoparticles showed the slowest decrease in particle size in 
SIF confirming them to be the most stable among the four modified silica nanoparticles. At 
intestinal pH (6.8), unmodified MCM-41 nanoparticles showed, significant reduction (p < 
0.05) of particle size from 149nm to 60nm in 96 hrs, most likely due to nanoparticles surface 
molecule undergoing hydrolysis at this pH. Therefore, to avoid this corrosive effect in 
nanoparticles structure, modification of nanoparticles surface with other functional groups 
would potentially be an advantage for achieving sustained release of antigen at intestinal pH. 
In figure 5b, APTES modified MCM-41 nanoparticles showed particle size reduced (p > 0.05) 
from 179nm to 126nm within 12 hrs, which can be explained by possible erosion of loose 
nanoparticle aggregates. PEG and chitosan modified MCM-41 nanoparticles showed negligible 
size reduction within 48 hrs and remained stable until 96 hrs.  
 The results suggest that, the stability of MCM-41 silica nanoparticles depends on their 
structure as well as the processing conditions. For example, the MCM-41-PEG modified 
nanoparticles were prepared at higher temperature (80ºC) to form core silica shell nanoparticles 
resulting in higher levels of polymerization, which showed better stability compared with 
unmodified MCM-41. It is possible that covalent pegylation on the nanoparticles surface would 
work as a driving force, maintaining particle dispersion and reducing aggregation tendencies, 
due to reduced carboxylic groups on the surface [26]. Recently some reports [1] indicated  that 
the presence of pore structures in unmodified silica nanoparticles also influences their stability 
in simulated fluids. The large surface area is due to high porosity which may lead to more 
vigorous erosion from the surrounding materials [27]. In addition, the encapsulation of external 
molecules in silica networks may also trigger disintegration of particles’ structure. Therefore, 
surface modification with amino and polymeric bearing groups could improve their stability, 
as has been shown in this study.              





3.7 Mucin binding analysis 
Since the ultimate objective of the surface modified silica nanoparticles was potential delivery 
to intestinal mucosa to achieve mucosal immune response, their mucoadhesive behavior was 
investigated by measuring the amount of mucin binding with the nanoparticles by Bradford 
protein assay. It has been reported [31] that MCM-41 nanoparticles showed low attraction with 
mucin and therefore required surface modification. It was observed (Table 2) that polymer 
modified MCM-41 nanoparticles showed good binding capability to mucin compared with the 
plain MCM-41 nanoparticles, with the unmodified MCM-41 nanoparticles showing mucin 
binding of 19% whilst PEG and chitosan modified nanoparticles showed 57 and 49% binding 
respectively. PEG and chitosan act as mucoadhesive polymers due to enhanced electrostatic 
interaction between negatively charged sialic acid residue of mucin and positively charged 
PEG and chitosan on modified MCM-41 nanoparticle surfaces. However, according to Table 
1, the modified MCM-41-PEG nanoparticles, which showed the highest mucin binding, were 
negatively charged with zeta potential value of -33mV. This will suggest that other mechanisms 
and factors beside the electrostatic interaction (possibly hydrogen bonding and van de Waals 
forces might be contributing to the mucin binding; however, this will require further 
investigation. 
 The mucoadhesive properties of chitosan and PEG are based on the hydrogen bonding 
between polyethylene oxide group of PEG and amino groups from chitosan. This interaction 
is very important to understand the cell interaction of nanoparticles leading to uptake and is an 
important requirement of mucosal delivery of therapeutics. APTES and PMMA modified 
nanoparticles showed lower mucin binding values of 26% and 41 % respectively compared 
with PEG and chitosan modified MCM-41 nanoparticles, due to the natural mucoadhesive 
properties of PEG and chitosan.  





3.8 Circular dichroism analysis of in vitro released OVA  
Circular dichroism (CD) is an excellent and sensitive method for rapidly evaluating the 
secondary structure, folding and binding properties of proteins and various research papers [32, 
33, 34]  have reported the detection of structural changes of proteins after interacting with 
nanoparticles. The CD spectra of OVA released from the various formulations are shown in in 
figure 6. In the case of MCM-41 PMMA, the OVA interaction with MCM-41 nanoparticles 
caused a clear change in the CD spectrum compared with the native protein. An analysis carried 
out using a set of reference CD spectra for α-helix, β-sheet, and irregular structures indicates 
that in the MCM-41 nanoparticles system the α-helical content of protein molecule were 
limited and probably resulting in an increase in the irregular structures. In the case of MCM-
41 APTES, the intensity of CD spectrum decreased significantly compared to the pure OVA, 
while retaining the original shape, indicating that the protein precipitates upon interaction with 
MCM-41 APTES nanoparticles. This effect was also seen during DLS analysis in Table 1 
which showed the formation in solution of some aggregates and large sized particles. The CD 
spectrum of OVA released from PMMA modified MCM-41 nanoparticles showed significant 
difference compared with pure OVA sample. The CD spectrum of OVA consists of α-helix 
signals including π-π at 208 and n-π at 220nm wavelength and its denaturation resulted in an 
attenuation of these CD signals. The CD spectra of OVA from PEG and chitosan modified 
sample, showed no significant difference from spectrum of pure OVA sample, and suggested 
that the protein underwent no significant denaturation on encapsulation and release from both 
modified MCM-41 nanoparticles. The porosity of these particles could play significant role in 
ensuring the maintenance of protein structure. At pH 6.8 OVA molecules would have 
significant negative charge and this charge build up within the constructed environment in the 
pores of the PEG and chitosan modified MCM-41 surface would have resulted in a greater 




degree of stability of the protein structure than the other nanoparticles with smaller pore sizes, 
therefore predominantly possessed surface adsorbed protein.           
 
3.9 SDS–PAGE analysis:  
Evidence for the presence of OVA during in vitro release from the nanoparticles was further 
confirmed using SDS-PAGE (Figure 7). SDS-PAGE is an excellent technique for separating 
macromolecules based on their weight as well as under the influence of an electric field and is 
therefore termed electrophoresis [35].  Bands were observed at 44kDa and no other bands were 
observed in comparison with pure OVA band (A) (figure 7), suggesting that the particles did 
not cleave the protein which indicates that the primary structure of the protein was not affected 
by the harsh nanoparticles formulation processing conditions. Uddin and Gill reported that 
OVA solution showed the presence of additional protein bands attributed to small quantities of 
ovotransferrin (76kDa) and lysozyme (14.4kDa) impurities, which are the two abundant egg 
white proteins [36] and which they referred to as residual proteins [37]  
 
3.10 Brunauer-Emmett-Teller (BET) analysis:  
Nitrogen-adsorption and desorption techniques were used to analyze the surface area, pore 
volume and pore size distribution of the formulated MCM-41 nanoparticles. Figure 8 exhibited 
typical type II isotherm as well as ordered porous structure, as judged by the hysteresis loops 
[38]. The BET surface area (SBET), pore volume (Vp) and pore diameter distribution are 
summarized in Table 3. MCM-41 blank nanoparticles in comparison with APTES and PMMA 
modified MCM-41 nanoparticles showed reduction in pore size from 5nm to 2.8 and 2.3nm 
respectively, after the modification which might be attributed to the blockage of pores during 
drying process. However, PEG and chitosan modified MCM-41 nanoparticles displayed high 
surface areas of 621m2g-1 and 641m2g-1, pore sizes of 3.2 and 3.5, as well as large pore volume 




0.80 and 0.77 cm3/g respectively. This is because the surface group introduced increased the 
mass of the sample and formed a part of the pore volume. The unchanged hysteresis loops and 
pore size confirmed that pores were not blocked during MCM-41 surface modification. In 
comparing between MCM-41 and functional modification of MCM-41 nanoparticles, it can be 
inferred that the distribution of the micropores shift or tails toward somewhat larger pore sizes 
as the synthesis temperature is increased. However, the pore diameter achieved for MCM-41 
PEG and chitosan modified nanoparticles was comparably higher than that of other research 
papers [39, 40] and this suggested that these surface modified MCM-41 nanoparticles would 
be suitable for protein encapsulation.           
 
4 Conclusions 
The main objective of this study was to develop strong core shell and porous MCM-41 
nanoparticles with surface modification to achieve maximum protein encapsulation and also 
be able to protect the protein from the harsh gastrointestinal environment to allow delivery to 
the target site within intestinal Peyer’s patches. Surface modified MCM-41 nanoparticles using 
polymer (PMMA, PEG, chitosan) and amine (APTES) changed their physicochemical 
properties, influencing the particle size, PDI, zeta potential as well protein loading efficiency 
and in vitro protein release profiles. The APTES, PEG and chitosan modified MCM-41 
nanoparticles released OVA in a controlled manner whilst unmodified MCM-41 nanoparticles 
showed faster release rate. Testing in the presence of simulated fluid (SGF and SIF) suggest 
that PEG and chitosan modified MCM-41 nanoparticles exhibited excellent stability, as well 
as high protein encapsulation profile. However, a further optimization of the release profile is 
required to decrease the protein release in the GIT environment as well as investigating the 
immunogenicity using an animal in vivo model to confirm the ability of the nanoparticles to 
deliver vaccines successfully using the oral route. Finally it can be concluded that, PEG and 




chitosan modified MCM-41 nanoparticles achieved significant increase of protein 
encapsulation efficiency in microporous protein host, provided protection of the encapsulated 
protein without any structural modification, produced spherical particles with appropriate 
porosity via an easy synthesis process, excellent mucin binding, and possessed high surface 




Figure 1 A) Representative SEM images of blank surface modified MCM-41 nanoparticle 
image B) Histogram showing particle size distribution of image A by ImageJ software. C) 
STEM image of typical blank MCM-41 nanoparticles. D) Histogram showing particle size 
distribution of image C by ImageJ software. E) Representative SEM image of OVA 
encapsulated surface modified MCM-41 nanoparticles. F) Histogram showing particle size 
distribution of image E by ImageJ software. G) STEM image of typical OVA encapsulated 
MCM-41 nanoparticles. H) Histogram showing particle size distribution of image G by 
ImageJ software.    
 
Figure 2 XRD diffractograms of (a) MCM-41 blank nanoparticles and (b) MCM-41 surface 
modified OVA encapsulated nanoparticles. 
 
Figure 3 ATR-FTIR spectra of (a) blank MCM-41 nanoparticles and (b) OVA encapsulated 
MCM-41 nanoparticles. 
 
Figure 4 In vitro protein release profiles (n = 3) of OVA in (a) in SGF (pH 1.2) and (b) in SIF 
(pH 6.8). 
 
Figure 5 MCM-41 nanoparticles stability studies (n = 3) in (a) SGF (pH 1.2) and (b) SIF (pH 
6.8). 
 




Figure 6 CD spectra of OVA released from various nanoparticle formulations 
 
Figure 7 SDS-PAGE analysis of OVA protein in (A) pure native OVA, (B) MCM-41-PEG (C) 
MCM-41-Chitosan (D) MCM-41-PMMA (E) MCM-41-APTES nanoparticles. 
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% (± SD) 
OVA loading 
capacity (LC) 
% (± SD) 
MCM-41 146 ± 5 0.21 ± 0.01 -37 ± 3 155 ± 7 0.24 ± 0.02 -39 ± 4 32 ± 2 28 ± 3 
MCM-41-APTES 175 ± 6 0.29 ± 0.04 +33 ± 5 203 ± 10 0.22 ± 0.01 -45 ± 9 69 ± 1 58 ± 1 
MCM-41-PMMA 211 ± 4 0.47 ± 0.10 +17 ± 2 256 ± 8 0.32 ± 0.01 -36 ± 3 22 ± 4 19 ± 2 
MCM-41-PEG 236 ± 5 0.25 ± 0.16 -33 ± 6 287 ± 5 0.46 ± 0.03 -39 ± 2 67 ± 5 53 ± 2 
MCM-41-chitosan 321 ± 11 0.37 ± 0.09 33 ± 4 416 ± 12 0.52 ± 0.02 -31 ± 5 73 ± 3 64 ± 1 









Table 2: In-vitro mucin binding analysis of MCM-41 nanoparticles. 6 
Formulation Mucin binding (%) 
MCM-41 19 ± 3% 
MCM-41-APTES 26 ± 5% 
MCM-41-PEG 59 ± 4% 
MCM-41-PMMA 41 ± 4% 
MCM-41-Chitosan 49 ± 2% 
  7 








Table 3: BET pore size, pore volume and surface area measurement of blank nanoparticles. 12 
Formulation name Pore size 
(nm) 




MCM-41 5.0 776 0.86 
MCM-41-APTES 2.8 655 0.74 
MCM-41-PMMA 2.3 535 0.66 
MCM-41-PEG 3.2 621 0.80 
MCM-41Chitosan  3.5 641 0.77 
 13 
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